GlassScriptPhysician profile
Robert Alan Whiddon
NPI 1376997205
$18,385.71
in general payments reported to CMS, 2019-2025
32 companies · $4,767 in 2025
The $4,767 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,600 · 2022: $3,014 · 2023: $3,761 · 2024: $5,245 · 2025: $4,767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,387.48 |
| Education | $384.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,937.53 | 2021-2025 | |
| Abbvie INC. | $2,842.58 | 2021-2025 | |
| Ucb, INC. | $1,275.95 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $1,128.48 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $1,081.92 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $906.25 | 2021-2025 | Winlevi, Ilumya, Blu-U |
| Pfizer INC. | $894.37 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $853.36 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $813.55 | 2022-2025 | Sotyktu |
| Incyte Corporation | $735.42 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $723.97 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $677.15 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Galderma Laboratories, L.P. | $599.38 | 2021-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $526.01 | 2023-2025 | Zoryve |
| Organogenesis INC. | $394.83 | 2024-2025 | Novachor, Puraply Wound Matrix, Via Matrix |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $382.72 | 2021-2025 | |
| Leo Pharma INC. | $265.86 | 2021-2025 | Adbry |
| Amgen INC. | $248.56 | 2021-2025 | Otezla, Enbrel |
| Revance Therapeutics, INC. | $221.53 | 2024-2025 | Daxxify |
| Sanofi-Aventis U.S. LLC | $170.84 | 2021-2024 | |
| Helsinn Therapeutics (U.S.), INC. | $150.34 | 2021-2025 | Valchlor |
| Botanix Sb INC | $132.26 | 2025 | Sofdra |
| Biofrontera INC. | $93.54 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $90.50 | 2022-2025 | Jublia, Cabtreo, Siliq |
| Organon LLC | $62.72 | 2025 | Vtama, Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.84 | 2023-2025 | Spevigo |
| Almirall LLC | $42.75 | 2024-2025 | Klisyri, Seysara |
| Journey Medical Corporation | $25.91 | 2021 | |
| Epi Health, LLC | $19.39 | 2022 | |
| Sandoz INC. | $17.86 | 2024 | Hyrimoz |
| Medtronic, INC. | $13.06 | 2023 | Venaseal |
| Paratek Pharmaceuticals, INC. | $12.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Whiddon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.